Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Ludwig Maximilian University Of Munich

Verified siteinfoFast reply

Germany Lindwurmstrasse 4, Ludwigsvorstadt-Isarvorstadt, 80337 Munich, Germany

  • 26 trials recruiting
  • HIV infection · Non-small cell lung cancer · Adrenogenital syndrome
  • Adults and children

About Specializations

Ludwig Maximilian University Of Munich in Munich, Germany specialises in clinical trials of conditions such as HIV infection, Non-small cell lung cancer, Adrenogenital syndrome, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Psychiatry and Psychology – Mental Disorders

The Ludwig Maximilian University Of Munich is conducting research focused on early-to-mild dementia due to Alzheimer's disease within the broader field of Psychiatry and Psychology. Trials aim to evaluate a potential therapeutic and diagnostic role of Thiethylperazine to improve brain amyloid‑β clearance and delay cognitive decline.

  • Investigating amyloid‑β clearance mechanisms
  • Assessing early diagnostic biomarkers
  • Exploring repurposed antipsychotic agents
  • Evaluating cognitive outcomes in mild dementia
  • Monitoring safety and tolerability over 12 months

A total of 6 trials involve 38 investigators, all centered at the Klinik und Poliklinik für Psychiatrie und Psychotherapie in Munich, Germany, advancing therapeutic options for patients with early Alzheimer's pathology.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Lindwurmstrasse 4, Ludwigsvorstadt-Isarvorstadt80337 MunichGermany
Open in maps ↗
Recruiting now
26 trials
Conditions studied
66
Partner status
Verified site

More sites in MunichGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

78 clinical trials

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

Dermatomyositis+1

Recruiting

Study on Anifrolumab for Adults with Polymyositis or Dermatomyositis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Sjogren's syndrome

Recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Immunoglobulin G4 related disease

Recruiting

A study to evaluate the efficacy and safety of rilzabrutinib in adults with active IgG4-related disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Hormone-dependent prostate cancer

Recruiting

A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:University College London

Neoplasm malignant+2

Recruiting

A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Ellipses Pharma Limited

Haemophilia

Recruiting

A study testing fitusiran to prevent bleeding in boys aged 1 to 11 years with hemophilia A or B with or without inhibitors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Fitusiran
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Depression

Recruiting

Testing dehydroepiandrosterone combined with standard antidepressants for patients with treatment-resistant depression

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lactose Monohydrate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Ischaemic stroke

Recruiting

Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Insel Gruppe AG

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International SA
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.